Mangoceuticals, Inc.
MGRX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.51% | -15.80% | 52.24% | 245.65% | 670.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.51% | -15.80% | 52.24% | 245.65% | 670.89% |
| Cost of Revenue | -33.04% | -21.37% | 54.52% | 256.44% | 578.99% |
| Gross Profit | -43.51% | -11.94% | 50.61% | 238.07% | 740.10% |
| SG&A Expenses | 1.48% | -11.74% | 16.43% | 31.28% | 91.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.97% | 2.41% | 27.20% | 46.13% | 118.35% |
| Operating Income | -15.05% | -4.10% | -25.28% | -37.67% | -103.36% |
| Income Before Tax | -23.95% | 5.48% | -27.45% | -40.12% | -97.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.95% | 5.48% | -27.45% | -40.12% | -97.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.94% | 5.49% | -27.43% | -40.11% | -97.83% |
| EBIT | -15.05% | -4.10% | -25.28% | -37.67% | -103.36% |
| EBITDA | -1.48% | 4.84% | -25.41% | -65.42% | -201.92% |
| EPS Basic | 38.64% | 46.44% | 27.43% | 16.50% | -18.25% |
| Normalized Basic EPS | 43.18% | 50.05% | 27.43% | 16.50% | -18.25% |
| EPS Diluted | 38.64% | 46.44% | 27.43% | 16.50% | -18.25% |
| Normalized Diluted EPS | 43.18% | 50.05% | 27.43% | 16.50% | -18.25% |
| Average Basic Shares Outstanding | 119.36% | 90.36% | 76.59% | 68.85% | 71.36% |
| Average Diluted Shares Outstanding | 119.36% | 90.36% | 76.59% | 68.85% | 71.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |